These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 38584216

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
    Sora F, Grazia CD, Chiusolo P, Raiola AM, Bregante S, Mordini N, Olivieri A, Iori AP, Patriarca F, Grisariu S, Terruzzi E, Rambaldi A, Sica S, Bruno B, Angelucci E, Bacigalupo A.
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):698-703. PubMed ID: 31875522
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 28. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
    Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Bonfichi M, Pagnucco G, Malcovati L, Varettoni M, Lazzarino M, Bernasconi C.
    Ann Hematol; 2001 Sep; 80(9):521-4. PubMed ID: 11669300
    [Abstract] [Full Text] [Related]

  • 29. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
    Rosser SPA, Brewer A, Gabriel M, Wong M, Chung J, McLachlan AJ, Nath CE, Keogh SJ, Shaw PJ.
    Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
    Mora E, Montoro J, Balaguer A, Rovira M, Cabrero M, Heras I, Ribera JM, Antelo G, Martin AA, Lopez Godino O, Torrent A, Villalba M, Chorao P, Sanz MA, Sanz J, Grupo Español de Trasplante Hematopoyético (GETH).
    Bone Marrow Transplant; 2024 Aug; 59(8):1137-1145. PubMed ID: 38755458
    [Abstract] [Full Text] [Related]

  • 32. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A.
    Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
    [Abstract] [Full Text] [Related]

  • 33. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S.
    Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
    [Abstract] [Full Text] [Related]

  • 34. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M.
    Dtsch Med Wochenschr; 2005 Sep 23; 130(38):2125-9. PubMed ID: 16172951
    [Abstract] [Full Text] [Related]

  • 35. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
    Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M, Depau C, Mico C, Santarone S, Angelucci E.
    Am J Hematol; 2008 Sep 23; 83(9):717-20. PubMed ID: 18626885
    [Abstract] [Full Text] [Related]

  • 36. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.
    Biol Blood Marrow Transplant; 2002 Sep 23; 8(9):468-76. PubMed ID: 12374451
    [Abstract] [Full Text] [Related]

  • 37. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.
    Biol Blood Marrow Transplant; 2012 Mar 23; 18(3):466-72. PubMed ID: 21963618
    [Abstract] [Full Text] [Related]

  • 38. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C.
    Biol Blood Marrow Transplant; 2016 Aug 23; 22(8):1424-1430. PubMed ID: 27154848
    [Abstract] [Full Text] [Related]

  • 39. A Very Rare Type of Leukemia in a Young Pediatric Patient Treated With Hematopoietic Stem Cell Transplantation: Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Tekkeşin F, Asarcikli F, Yildirim ÜM, Zemheri IE, Kiliç SÇ.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e288-e291. PubMed ID: 33235146
    [Abstract] [Full Text] [Related]

  • 40. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
    Chiusolo P, Bregante S, Giammarco S, Lamparelli T, Casarino L, Dominietto A, Raiola AM, Metafuni E, Di Grazia C, Gualandi F, Sora F, Laurenti L, Sica S, Barosi G, Guolo F, Rossi M, Rossi E, Vannucchi A, Signori A, De Stefano V, Bacigalupo A, Angelucci E.
    Am J Hematol; 2021 Feb 01; 96(2):234-240. PubMed ID: 33146914
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.